A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors

Inclusion Criteria:

- Histologically confirmed advanced solid tumors with measurable lesions per RECIST v1.1
that are considered nonamenable to surgery or other curative treatments or procedures.

- Must have received or been intolerant to standard therapy.

- Eastern Cooperative Oncology Group performance status score of 0 or 1.

- Willingness to avoid pregnancy or fathering children as per protocol-defined criteria.

Exclusion Criteria:

- Laboratory values not within the protocol-defined range.

- History of retinal disease as defined in the protocol.

- Clinically significant cardiac disease as per protocol-defined criteria.

- History or presence of an ECG that, in the investigator's opinion, is clinically
meaningful as per protocol-defined criteria.

- Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases
that have progressed as per protocol-defined criteria.

- Active or inactive autoimmune disease or syndrome that has required systemic treatment
in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory
disease.

- Prior Grade 3 or higher immune-related AEs or any ocular toxicity on prior
immunotherapy as per protocol-defined criteria.

- Receipt of any vitamin K antagonists, systemic corticosteroids, live vaccines, or
treatment with any anticancer medications or investigational drugs within the
protocol-defined intervals.

- Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy and/or
complications from prior surgical intervention before starting study treatment.

- Active infection requiring systemic therapy.

- Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.

- Known history of HIV (HIV 1/2 antibodies).